title: Small cell carcinoma of the urinary bladder. A clinicopathologic study of five cases.
abstract: OBJECTIVE
  Small cell carcinoma of the bladder (SCCB) is a rare entity characterized clinically by an aggressive behavior with a high incidence of systemic metastases. We report the clinicopathologic findings of five cases.
  
  
  METHODS
  We reviewed five consecutive patients with SCCB treated at our institute. In each case the following clinical data were recorded: age, sex, presenting symptoms, endoscopically determined location of the tumor, clinical staging, node involvement (if any), site of metastases (if any), treatment, follow-up and outcome.
  
  
  RESULTS
  There were four male and one female patients, age range 42 to 68 years, mean 57.6 years. The clinical presentation was not different from conventional transitional cell carcinoma, with hematuria being the most frequent complaint (four cases). Microscopic examination revealed oat cells in three cases and an intermediate variant in one. At the time of diagnosis the tumors were staged as T3bN2M0, T2N2M0, T4N0M0, T3aN0M0, and T2N0M0. Primary therapy consisted of radical cystectomy alone (one case), transurethral resection (TUR) alone (one case), TUR with chemotherapy (two cases), or TUR with chemotherapy and radiotherapy (one case). Four patients died of progressive disease, with survival from the time of diagnosis ranging from 7 to 16 months (mean, 12.2 months). One patient died of myocardial infarction (unrelated to the primary disease) one month after diagnosis.
  
  
  CONCLUSIONS
  Our study indicates that primary small cell carcinoma of the urinary bladder is as aggressive as its pulmonary counterpart and the overall prognosis of this tumor is very poor.
authors.affiliation: Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey. ozkanat@uludag.edu.tr
authors.forename: Ozkan
authors.initials: O
authors.lastname: Kanat
authors.forename: Turkkan
authors.initials: T
authors.lastname: Evrensel
authors.forename: Saduman Balaban
authors.initials: SB
authors.lastname: Adim
authors.forename: Ismet
authors.initials: I
authors.lastname: Yavascaoglu
authors.forename: Ender
authors.initials: E
authors.lastname: Kurt
authors.forename: Mutlu
authors.initials: M
authors.lastname: Demiray
authors.forename: Guzin
authors.initials: G
authors.lastname: Gonullu
authors.forename: Osman
authors.initials: O
authors.lastname: Manavoglu
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000473:pathology*; D015653:Cystectomy; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D016130:Immunophenotyping; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000473:pathology; D009367:Neoplasm Staging; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000473:pathology*